Cargando…
A Point-of-Care Interactive Decision Tool Reveals Variance Between Clinicians and Experts in Selecting Among GLP-1 RAs in T2D
Background: T2D management is shifting toward treating patients with therapies that align with their level of CV and end-organ risk. To this end, evidence-based guidelines now recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for both glycemic and extraglycemic benefits. The great spee...
Autores principales: | Schwartz, Zachary, Mir-Hudgeons, Kiran, Roc, Anne, Zimmerman, Robert S, Peters, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089797/ http://dx.doi.org/10.1210/jendso/bvab048.949 |
Ejemplares similares
-
SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
por: Larkin, Amy, et al.
Publicado: (2019) -
Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021) -
SUN-148 Are Glp Analogues Superior For Diabetes And Weight Control In Patients On Antidepressant Medications?
por: Azim, Salman, et al.
Publicado: (2019) -
MON-666 Glucokinase Within the Hypothalamic Paraventricular Nucleus Is Important in GLP-1 Release
por: Ratnasabapathy, Risheka
Publicado: (2020) -
MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)